Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

  Exhibit 10.01    
    

 
    INDEMNITY AGREEMENT    
    

        This Indemnity Agreement (this "Agreement"), dated as of    ,
20    , is made by and between Keynote Systems, Inc., a Delaware corporation (the "Company"),
and                , a director and/or
officer of the Company (the "Indemnitee"). 

 
 

  RECITALS    
    

        A.    The
Company is aware that competent and experienced persons are increasingly reluctant to serve as directors or officers of corporations unless they are protected by
comprehensive liability insurance and/or indemnification, due to their increased exposure to litigation costs and risks resulting from their service to such corporations, and due to the fact that this
exposure frequently bears no reasonable relationship to the compensation of such directors and officers; 

        B.    The
Board of Directors of the Company (the "Board") has determined that uncertainties relating to the availability,
expense and scope of the protection afforded by liability insurance and uncertainties regarding the availability and scope of indemnification have increased the difficulty of attracting and retaining
competent and experienced persons to serve as directors and officers, and that this situation is detrimental to the best interests of the Company and its stockholders; 

        C.    Based
on the experience of its members, the Board has concluded that, to retain and attract talented and experienced individuals to serve as officers and directors of the
Company, and to encourage such individuals to make the business decisions and take the business risks necessary for the success of the Company, it is reasonable, prudent and necessary for the Company
to contractually obligate itself to indemnify, and to advance expenses on behalf of, officers and directors and to assume for itself maximum liability for expenses and damages in connection with
claims against such officers and directors in connection with their service to the Company (including service in such capacities during time periods occurring prior to the date this Agreement is
executed); 

        D.    Section 145
of the General Corporation Law of Delaware, under which the Company is organized (the "Law"), empowers
the Company to indemnify by agreement its officers, directors, employees and agents, and persons who serve, at the request of the Company, as directors, officers, employees or agents of other
corporations or enterprises, and expressly provides that the indemnification provided by the Law is not exclusive; 

        E.    The
Company has requested the Indemnitee to serve or continue to serve as a director or officer of the Company and desires that the Indemnitee do so free from undue
concern for claims for damages arising out of or related to such services to the Company that may impede the free exercise of the Indemnitee's business judgment on behalf of the Company; and 

        F.     The
Indemnitee is willing to serve and to continue to serve the Company on the condition that the Indemnitee is indemnified and afforded rights to the advancement of
expenses as provided in this Agreement. 

 
 

  AGREEMENT    
    

        NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as
follows: 

        1.    Definitions.    

        1.1    Agent.    An "Agent" of the Company means any person who is or
was a director or officer of the Company or a subsidiary of the Company; or is or was serving at the request of, for the convenience of, or to represent the interest of the Company or a subsidiary of
the Company as a director or officer of another foreign or domestic corporation, partnership, joint venture, limited liability company, trust or other enterprise or an affiliate of the Company; or was
a director or officer of a foreign or domestic corporation which was a predecessor corporation of the Company, including, without limitation, Keynote Systems, Inc., a California corporation, or
was a director or 

 

officer
of another enterprise or affiliate of the Company at the request of, for the convenience of, or to represent the interests of such predecessor corporation. The term
"enterprise" includes, without limitation, any employee benefit plan of the Company, its subsidiaries, affiliates and predecessor corporations. 

        1.2    Change of Control.    A "Change of Control" shall be deemed to
have occurred if, after the Effective Date: (i) any "person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the
"1934 Act")), other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or a corporation owned directly
or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, is or becomes the "beneficial owner" (as defined in
Rule 13d-3 under the 1934 Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company's then
outstanding securities without the prior approval of at least two-thirds of the members of the Board in office immediately prior to such person attaining such percentage interest;
(ii) the Company is a party to a consummated merger, consolidation, or sale of assets of the Company, as a consequence of which the members of the Board in office immediately prior to the
consummation of such transaction constitute less than a majority of the members of the Board immediately after the consummation of such transaction; (iii) the stockholders of the Company
approve a plan of complete liquidation or dissolution of the Company or an agreement for the sale or disposition by the Company (in one transaction or a series of transactions) of all or substantially
all of the Company's assets; or (iv) during any period of twenty-four consecutive months, other than as a result of an event described in clause (ii) or clause (iii)
of this paragraph, the Incumbent Directors cease for any reason to constitute at least a majority of the members of the Board. For purposes of the foregoing clause (iv), with respect to any
particular twenty-four month period, the term "Incumbent Directors" means (A) the individuals who at the beginning of such
twenty-four month period constituted the
Board and (B) each other individual whose election to the Board during such twenty-four month period or whose nomination for election to the Board by the Company's stockholders
during such twenty-four month period was approved by a vote of at least two-thirds of the directors in office who were either members of the Board at the beginning of such
twenty-four month period or whose election or nomination for election to the Board was approved as described in this clause (B). 

        1.3    Company.    The term the "Company" shall include, in addition
to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have
had power and authority to indemnify its agents so that, if Indemnitee is or was an agent of such constituent corporation, or is or was serving at the request of such constituent corporation as an
agent of another corporation or other enterprise, then from and after the consummation of such merger or consolidation the Indemnitee shall stand in the same position under the provisions of this
Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued. 

        1.4    Disinterested Director.    The term "Disinterested Director"
means a member of the Board who is not and was not a party to a proceeding (as defined below) in respect of which indemnification is sought by the Indemnitee. 

        1.5    Expenses.    The term "Expenses" includes all direct and
indirect costs of any type or nature whatsoever (including, without limitation, all attorneys' fees and related disbursements and other out-of-pocket costs) actually and
reasonably incurred by the Indemnitee in connection with the investigation, defense or appeal of, or being a witness in or otherwise participating in (including on appeal), or preparing to defend, to
be a witness in or otherwise participate in, a proceeding or establishing or enforcing a right to indemnification or advancement of expenses 

2

 

under
this Agreement, Section 145 or otherwise; provided, however, that the term expenses shall not include any judgments, fines, ERISA excise taxes, or penalties or amounts paid in settlement
of a proceeding. 

        1.6    Independent Counsel.    The term "Independent Counsel" means a
law firm, or an attorney-at-law, that is experienced in matters of corporation law and neither presently is, nor in the past three years has been, retained to represent:
(i) the Company or the Indemnitee in any matter material to the Company or the Indemnitee, or (ii) any other party to the proceeding giving rise to a claim for indemnification or
advancement of expenses under this Agreement. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct
then prevailing, would have a conflict of interest in representing either the Company or the Indemnitee in an action to determine the Indemnitee's rights under this Agreement. The Company agrees to
pay the reasonable fees and expenses of the Independent Counsel referred to above incurred in performing any function or service in accordance with this Agreement which expressly contemplates the
participation of Independent Counsel and, if requested to do so by such Independent Counsel, the Company will enter into an indemnification agreement mutually agreed to by the Company and Independent
Counsel at the time Independent Counsel is engaged. 

        1.7    Proceeding.    The term "Proceeding" means any threatened,
pending or completed action, suit, alternative dispute resolution mechanism (including but not limited to an arbitration or mediation) or other proceeding, whether civil, criminal, administrative,
investigative or any other type whatsoever, or any hearing, inquiry or investigation that the Indemnitee in good faith believes might lead to the institution of any such action, suit, arbitration,
mediation, alternative dispute resolution mechanism or other proceeding. 

        1.8    Subsidiary.    The term "Subsidiary" means any corporation of
which more than fifty percent (50%) of the outstanding voting securities is owned directly or indirectly by the Company, by the Company and one or more of its subsidiaries or by one or more of the
Company's subsidiaries. 

        2.    Agreement to Serve.    The Indemnitee agrees to serve and/or
continue to serve as an agent of the Company, at the will of the Company (or under separate agreement, if such agreement exists), in the capacity the Indemnitee currently serves as an agent of the
Company, faithfully and to the best of the Indemnitee's ability, so long as the Indemnitee is duly appointed or elected and qualified in accordance with the applicable provisions of the Bylaws or the
charter documents of the Company or any subsidiary of the Company; provided, however, that the
Indemnitee may at any time and for any reason resign from such position (subject to any contractual obligation that the Indemnitee may have assumed apart from this Agreement), and the Company or any
subsidiary shall have no obligation under this Agreement to continue the Indemnitee in any such position. 

        3.    Directors' and Officers' Insurance.    The Company shall, to the
extent that the Board determines it to be economically reasonable, maintain a policy of directors' and officers' liability insurance ("D&O Insurance"),
on such terms as may be approved from time to time by the Board. 

        4.    Mandatory Indemnification.    

        4.1    Third Party Actions.    If the Indemnitee is a person who was or is a party to, or is threatened to be made a
party to, any proceeding (other than an action by or in the right of the Company) by reason of the fact that the Indemnitee is or was an agent of the Company, or by reason of anything done or not done
by the Indemnitee in the Indemnitee's capacity as an agent of the Company, then, subject to the provisions of Section 8 of this Agreement and the exceptions set forth in Section 9, the
Company shall indemnify the Indemnitee against any and all expenses and liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise 

3

 

taxes
or penalties and amounts paid in settlement) actually and reasonably incurred by the Indemnitee in connection with the investigation, defense, settlement or appeal of, or being a witness in or
participating in (including on appeal) or preparing to defend, to be a witness in or to participate in, such proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably
believed to be in, or not opposed to, the best interests of the Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe the Indemnitee's conduct was
unlawful. 

        4.2    Derivative Actions.    If the Indemnitee was or is a party to, or is threatened to be made a party to, any
proceeding by or in the right of the Company to procure a judgment in its favor by reason of the fact that the Indemnitee is or was an agent of the Company, or by reason of anything done or not done
by the Indemnitee in the Indemnitee's capacity as an agent of the Company, then, subject to the provisions of Section 8 of this Agreement and the exceptions set forth in Section 9, the
Company shall indemnify the Indemnitee against any amounts paid in settlement of any such proceeding and all expenses actually and reasonably incurred by the Indemnitee in connection with the
investigation, defense, settlement or appeal of, or being a witness in or participating in (including on appeal) or preparing to defend, to be a witness in or to participate in, such proceeding if
Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company; except
that no indemnification under this subsection 4.2 shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged to be liable to the Company by a
court of competent jurisdiction, unless and only to the extent that the Court of Chancery or the court in which such proceeding was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such amounts which the Court of Chancery or such other court
shall deem proper. 

        4.3    Witness Expenses in Certain Proceedings.    Notwithstanding any other provision of this Agreement to the
contrary, to the extent that the Indemnitee was or is, by reason of the fact that the Indemnitee is or was an agent of the Company, a witness or other non-party participant in any
proceeding to which the Indemnitee is not made a party then the Company shall indemnify the
Indemnitee against all expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee's behalf solely in connection with the Indemnitee's being a witness or other
non-party participant in such proceeding (including on appeal), and in preparing to be a witness or such other non-party participant in such proceeding without the need for any
determination with respect to the Indemnitee's conduct pursuant to Section 8 of this Agreement. 

        4.4    Company Obligations Primary.    The Company hereby acknowledges that Indemnitee may have rights to
indemnification for Expenses and Other Liabilities provided by a person other than the Company ("Other Indemnitor"). The Company agrees with Indemnitee
that the Company is the indemnitor of first resort of Indemnitee with respect to matters for which indemnification is provided under this Agreement and that the Company will be obligated to make all
payments due to or for the benefit of Indemnitee under this Agreement without regard to any rights that Indemnitee may have against the Other Indemnitor. The Company hereby waives any equitable rights
to contribution or indemnification from the Other Indemnitor in respect of any amounts paid to Indemnitee hereunder. The Company further agrees that no reimbursement of Other Liabilities or payment of
Expenses by the Other Indemnitor to or for the benefit of Indemnitee shall affect the obligations of the Company hereunder, and that the Company shall be obligated to repay the Other Indemnitor for
all amounts so paid or reimbursed to the extent that the Company has an obligation to indemnify Indemnitee for such Expenses or Other Liabilities hereunder. 

        4.5    Exception for Amounts Covered by Insurance.    Notwithstanding the foregoing, the Company shall not be
obligated to make any separate payments to Indemnitee for expenses or 

4

 

liabilities
of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) to the extent D&O Insurance covers such expenses or
liabilities and the carrier of the D&O Insurance makes payment for such expenses and/or liabilities directly to the Indemnitee. To the extent that any payment payable by the carrier of the D&O
Insurance in respect of such expenses or liabilities has previously been paid or advanced to the Indemnitee by the Company, the parties agree that the Company shall be subrogated to the rights of the
Indemnitee to receive such payments from the D&O Insurance carrier and that the Indemnitee will take all actions reasonably necessary to turn over or otherwise cause the Company to receive such
payment from the D&O Insurance carrier. 

        4.6    Change in Law.    In the event of any change, after the date of this Agreement, in any applicable law, statute
or rule which expands the Company's right, as a Delaware corporation, to indemnify an Indemnifiable Person, such changes shall be, ipso facto, within
the purview of Indemnitee's rights and
Company's obligations, under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the Company's right, as a Delaware corporation, to indemnify an
Indemnifiable Person, such changes, to the extent required by such law, statute or rule to be applied to this Agreement, shall have the effect on this Agreement and the parties' rights and obligations
hereunder as is required by such law, statute or rule. 

        5.    Partial Indemnification and Contribution.    

        5.1    Partial Indemnification.    If the Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of any expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties and amounts
paid in settlement) incurred by Indemnitee in the investigation, defense, settlement or appeal of, or preparing to defend, to be a witness in or to participate in, a proceeding but the Indemnitee is
not entitled, however, to indemnification for the total amount thereof, then the Company shall nevertheless indemnify the Indemnitee for such total amount except as to the portion thereof to which the
Indemnitee is not entitled to indemnification. 

        5.2    Contribution.    If the Indemnitee is not entitled to the indemnification provided in Section 4 for any
reason other than the statutory limitations set forth in the Law or the provisions of Section 9, then in respect of any threatened, pending or completed proceeding in which the Company is
jointly liable with the Indemnitee (or would be if joined in such proceeding), the Company shall contribute to the amount of expenses (including attorneys' fees), judgments, fines, ERISA excise taxes
or penalties and amounts paid in settlement actually and reasonably incurred and paid or payable by the Indemnitee in such proportion as is appropriate to reflect (i) the relative benefits
received by the Company on the one hand and the Indemnitee on the other hand from the transaction from which such proceeding arose and (ii) the relative fault of the Company on the one hand and
of the Indemnitee on the other hand in connection with the events which resulted in such expenses, judgments, fines, ERISA excise taxes, penalties or settlement amounts, as well as any other relevant
equitable considerations. The relative fault of the Company on the one hand and of the Indemnitee on the other hand shall be determined by reference to, among other things, the parties' relative
intent, knowledge, access to information and opportunity to correct or prevent the circumstances resulting in such expenses, judgments, fines, ERISA excise taxes, penalties or settlement amounts. The
Company agrees that it would not be just and equitable if contribution pursuant to this Section 5 were determined by pro rata allocation or any other method of allocation which does not take
account of the foregoing equitable considerations. 

        6.    Mandatory Advancement of Expenses.    

        6.1    Advancement.    Subject to the exceptions in Section 9 below, the Company shall advance all expenses
actually and reasonably incurred by the Indemnitee in connection with the investigation, defense, settlement or appeal of, or Indemnitee being a witness in or participating in 

5

 

(including
on appeal), or preparing to defend, to be a witness in or to participate in, any proceeding to which the Indemnitee is a party or witness or other participant in, or is threatened to be
made a party to or witness or other participant in, by reason of the fact that the Indemnitee is or was an agent of the Company or by reason of anything done or not done by Indemnitee in any such
capacity. The Indemnitee hereby undertakes to promptly repay to the Company such amounts advanced by the Company to the Indemnitee only if, and to the extent that, it shall ultimately be determined
that the Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the Certificate of Incorporation or Bylaws of the Company, the Law or otherwise with
respect to the proceeding in respect of which such amounts were advanced. The advances to be made hereunder shall be paid by the Company to the Indemnitee within thirty (30) days following
delivery of a written request therefor by the Indemnitee to the Company. Such request shall reasonably evidence the expenses incurred by the Indemnitee (such as, for example, by submission of invoices
from third parties for such expenses). 

        7.    Notice and Other Indemnification Procedures.    

        7.1    Notice of Proceeding.    Promptly after receipt by the Indemnitee of notice of the commencement of or the
threat of commencement of any proceeding, the Indemnitee shall, if the Indemnitee believes that indemnification with respect to such proceeding may be sought from the Company under this Agreement,
notify the Company of the commencement or threat of commencement thereof. 

        7.2    Notice to D&O Insurance Carrier.    If, at the time of the receipt of a notice of the commencement of a
proceeding pursuant to Section 7.1 hereof, the Company has D&O Insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurer or insurers
providing such D&O Insurance in accordance with the procedures set forth in the respective D&O Insurance policies. The Company shall thereafter take all necessary or desirable action to cause such
insurers to pay, on behalf of the Indemnitee, all amounts payable by such insurers as a result of such proceeding in accordance with the terms of such D&O Insurance policies. 

        7.3    Assumption of Defense by Company.    In the event the Company shall be obligated to advance the expenses for
any proceeding against the Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by the Indemnitee (which approval shall not be
unreasonably withheld), upon the Company's delivery to the Indemnitee of written notice of the Company's election to do so. After delivery of such notice, approval of such counsel by the Indemnitee
and the retention of such counsel by the Company, the Company will not be liable to the Indemnitee under this Agreement for any fees of counsel subsequently incurred by the Indemnitee with respect to
the same proceeding, provided that: (a) the Indemnitee shall have the right to employ his or her own
counsel in any such proceeding at the Indemnitee's expense; (b) the Indemnitee shall have the right to employ his or her own counsel in connection with any such proceeding, at the expense of
the Company, if such counsel serves only in a review, observer, advice and counseling capacity and does not otherwise materially control or participate in the defense of such proceeding; and
(c) if (i) the employment of counsel by the Indemnitee has been previously authorized by the Company, (ii) the Indemnitee shall have reasonably concluded that there may be a
conflict of interest between the Company and the Indemnitee in the conduct of any such defense or (iii) the Company shall not, in fact, have employed counsel to assume the defense of such
proceeding, then the fees and expenses of the Indemnitee's counsel shall be at the expense of the Company. The Company shall not be required to obtain the consent of the Indemnitee to the settlement
of any proceeding as to which the Company has assumed the defense of the Indemnitee if the Company assumes full and sole responsibility and liability for such settlement and the settlement grants the
Indemnitee a complete and unqualified release in respect of the potential liability arising from such proceeding. 

6

 

 

        8.    Determination of Right to Indemnification.    

        8.1    Indemnitee Successful on the Merits.    To the extent the Indemnitee has been successful on the merits or
otherwise in defense of any proceeding referred to in Section 4.1 or 4.2 of this Agreement or in the defense of any claim, issue or matter described therein, the Company shall indemnify the
Indemnitee against all expenses actually and reasonably incurred by the Indemnitee in connection with the investigation, defense or appeal of such proceeding, or Indemnitee being a witness or other
participant in such proceeding. 

        8.2    Indemnitee Not Successful on the Merits.    In the event that Section 8.1 is inapplicable, or does not
apply to the entire proceeding, the Company shall nonetheless indemnify the Indemnitee as provided in Section 4.1 or 4.2, as applicable, unless the Company shall claim and prove by clear and
convincing evidence to a forum listed in Section 8.4 below that (i) the Indemnitee has not met the applicable standard of conduct required to entitle the Indemnitee to such
indemnification, or (ii) Indemnitee is not entitled to indemnification because one or more of the exceptions in Section 9 is applicable. 

        8.3    Witness Expenses if Section 4.3 Applies.    In the event that the provisions of Section 4.3 apply
because the Indemnitee was not a party to the proceeding, the Company shall indemnify the Indemnitee against all expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee's
behalf in connection with being a witness or other non-party participant in such proceeding (including on appeal), and in preparing to be a witness or such other non-party
participant in such proceeding. 

        8.4    Selection of Forum to Determine Entitlement to Indemnification.    If the Company claims that the Indemnitee is
not entitled to indemnification pursuant to Sections 4.1 or 4.2, then the Indemnitee shall be entitled to select the forum in which the validity of the Company's claim that the Indemnitee is
not entitled to indemnification shall be heard from among the following: 

        (a)   A
majority of the members of the Board who are Disinterested Directors with respect to the proceeding for which indemnification is being sought by the Indemnitee;; 

        (b)   Independent
Counsel selected by the Indemnitee, and reasonably approved by the Board, which Independent Counsel shall make such determination in a written opinion; or 

        (c)   A
panel of three arbitrators, one of whom is selected by the Company, another of whom is selected by the Indemnitee and the last of whom is selected by the first two
arbitrators so selected who will conduct the determination in San Francisco, California pursuant to the Commercial Arbitration Rules of the American Arbitration Association; or 

        (d)   The
Delaware Chancery Court or a state or federal court where the Company's principal place of business is located. 

        8.5    Procedure for Determination.    As soon as practicable, and in no event later than 30 days after written
notice of the Indemnitee's choice of forum pursuant to Section 8.4, the Company shall, at its own expense, submit to the selected forum, in such manner as the Indemnitee or the Indemnitee's
counsel may reasonably request, its claim under Section 8.2 that the Indemnitee is not entitled to indemnification, and the Company shall act in the utmost good faith to assure the Indemnitee a
complete opportunity to defend against such claim. The Indemnitee shall cooperate with the forum making such determination with respect to the Indemnitee's entitlement to indemnification, including
providing to such forum upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to the
Indemnitee and reasonably necessary to such determination. 

        8.6    Effect of Determination.    If the forum selected in accordance with Section 8.4 determines that the
Indemnitee is entitled to indemnification with respect to a specific proceeding, then such 

7

 

determination
shall be final and binding on the Company, the Company shall indemnify the Indemnitee to the extent so determined by such forum and payment of such indemnification shall be made by the
Company within thirty (30) days after such determination. If the forum selected in accordance with Section 8.4 determines that the Indemnitee is not entitled to indemnification with
respect to a specific proceeding, then the Indemnitee shall have the right to apply to the Court of Chancery of Delaware, the court in which that proceeding is or was pending or any other court of
competent jurisdiction, for the purpose of appealing such determination and obtaining an adjudication by such court of the Indemnitee's entitlement to such indemnification pursuant to this Agreement
with respect to such proceeding, provided that such right is exercised by the Indemnitee within sixty (60) days after the final decision of such
forum is rendered. The Company shall not oppose the Indemnitee's right to seek any such adjudication, and any such judicial adjudication shall be conducted in all respects as a  de novo trial on the
merits, such that any determination made by any forum selected in accordance with Section 8.4 that the Indemnitee is not
entitled to be indemnified hereunder shall not be binding on any such court and the Indemnitee shall not be prejudiced by reason of any such determination by such forum. If the forum selected in
accordance with Section 8.4 to determine whether the Indemnitee is entitled to indemnification shall not have made a determination within 120 days after the date on which the Company is
required by Section 8.5 to submit to such forum its claim that the Indemnitee is not entitled to such indemnification, then the Indemnitee shall be entitled to apply to the Court of Chancery of
Delaware to have the Indemnitee's request for indemnification adjudicated by such Court in lieu of having the determination made by such forum. The Company shall not oppose the Indemnitee's right to
seek any such adjudication. 

        8.7    No Presumption.    For purposes of this Agreement, the termination of any proceeding by judgment, order,
settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that the Indemnitee did not meet any particular
standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by this Agreement or applicable law. In addition, neither the failure of any
forum selected in accordance with Section 8.4 to have made a determination as to whether the Indemnitee has met any particular standard of conduct or had any particular belief, nor an actual
determination by any such selected forum that the Indemnitee has not met such standard of conduct, shall be a defense to the Indemnitee's claim for indemnification or create a presumption that the
Indemnitee has not met any particular standard of conduct or did not have any particular belief. In connection with any determination by any selected forum or otherwise as to whether the Indemnitee is
entitled to be indemnified hereunder, the burden of proof shall be on the Company to establish that the Indemnitee is not so entitled. 

        8.8    Certain Expenses.    Notwithstanding any other provision in this Agreement to the contrary, the Company shall
indemnify the Indemnitee against all expenses incurred by the Indemnitee in connection with any hearing or proceeding under this Section 8 (including any adjudication before the court
contemplated by the foregoing provisions of this Section 8) involving the Indemnitee and against all expenses incurred by the Indemnitee in connection with any other proceeding between the
Company and the Indemnitee involving the interpretation or enforcement of the rights of the Indemnitee under this Agreement unless a court of competent jurisdiction finds that each of the material
claims and/or defenses of the Indemnitee in any such proceeding was frivolous or not made in good faith. 

        9.    Exceptions.    Any other provision herein to the contrary notwithstanding, the Company
shall not be obligated pursuant to the terms of this Agreement: 

        9.1    Claims Initiated by Indemnitee.    To indemnify or advance expenses to the Indemnitee with respect to
proceedings or claims initiated or brought voluntarily by the Indemnitee and not by way of defense, except with respect to proceedings specifically
authorized by the Board or brought 

8

 

to
establish or enforce a right to indemnification and/or advancement of expenses arising under this Agreement, the Bylaws or charter documents of the Company or any subsidiary or any statute or law
or otherwise, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the Board finds it to be appropriate; or 

        9.2    Unauthorized Settlements.    To indemnify the Indemnitee hereunder for any amounts paid in settlement of a
proceeding unless the Company consents in advance in writing to such settlement, which consent shall not be unreasonably withheld; or 

        9.3    Section 16(b) Actions.    To indemnify the Indemnitee on account of any suit in which judgment is
rendered against the Indemnitee for an accounting of profits made from the purchase or sale by the Indemnitee of securities of the Company pursuant to the provisions of Section 16(b) of the
Securities Exchange Act of 1934 and amendments thereto or similar provisions of any federal, state or local statutory law; or 

        9.4    Unlawful Indemnification.    To indemnify the Indemnitee if a final decision by a court having jurisdiction in
the matter shall determine that such indemnification is not lawful. In this respect, the Company and the Indemnitee have been advised that the Securities and Exchange Commission takes the position
that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable and that claims for indemnification should be submitted to
appropriate courts for adjudication. 

        10.    Non-Exclusivity.    The provisions for indemnification and advancement of
expenses set forth in this Agreement shall not be deemed exclusive of, or a substitute for, or to diminish or abrogate, any other rights which the Indemnitee may have under any provision of law, the
Company's Certificate of Incorporation or Bylaws, the vote of the Company's stockholders or Disinterested Directors, other agreements or otherwise, both as to action in the Indemnitee's official
capacity and to action in another capacity while occupying his or her position as an agent of the Company; provided, however, that this Agreement shall
supersede and replace that certain Indemnity Agreement between the Indemnitee and the Company entered into prior to the Effective Date (the "Prior Indemnity
Agreement"), except that, to the extent that superseding or replacing the Prior Indemnity Agreement with this Agreement would
for any reason result in the Indemnitee not being entitled to rights under this Agreement with respect to any proceeding arising out of any facts, events or circumstances occurring prior to the
Effective Date of this Agreement (a "Pre-Existing Proceeding"), then, in such case only, the Indemnitee's rights and obligations under the
Prior Indemnity Agreement will survive, but only with respect to any such Pre-Existing Proceeding. The Indemnitee's rights hereunder shall continue after the Indemnitee has ceased acting
as an agent of the Company and shall inure to the benefit of the heirs, executors and administrators of the Indemnitee. No amendment, alteration or repeal of this Agreement or of any provision hereof
shall limit or restrict any right of the Indemnitee under this Agreement in respect of any action taken or omitted by the Indemnitee as an agent prior to such amendment, alteration or repeal. To the
extent that a change in the Law, whether by statue or judicial decision, permits greater indemnification or advancement of expenses than would be afforded currently under the Company's Bylaws and this
Agreement, it is the intent of the parties hereto that the Indemnitee shall enjoy by this Agreement the greater benefits afforded by such change. The assertion or employment of any right or remedy
hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 

        11.    Good Faith Safe Harbor.    

        For
purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee's action is based on the records or books of account of the Company,
including financial statements, or on information supplied to Indemnitee by the officers of the Company in the course of their duties, or on the advice of legal counsel for the Company or on
information or records given or reports made to the Company by an independent certified public 

9

 

accountant
or by an appraiser or other expert selected with the reasonable care by the Company. The provisions of this Section 11 shall not be deemed to be exclusive or to limit in any way the
other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. 

        12.    General Provisions.    

        12.1    Interpretation of Agreement.    It is understood that the parties hereto intend this Agreement to be
interpreted and enforced so as to provide indemnification and advancement of expenses to the Indemnitee to the fullest extent now or hereafter permitted by law, except as expressly limited herein. 

        12.2    Severability.    If any provision or provisions of this Agreement shall be held to be invalid, illegal or
unenforceable for any reason whatsoever, then: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, all portions of any
paragraphs of this Agreement containing any such provision held to be invalid, illegal or unenforceable that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or
impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, all portions of any paragraphs of this Agreement containing any such
provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision
held invalid, illegal or unenforceable and to give effect to Section 12.1 hereof. 

        12.3    Modification and Waiver.    No supplement, modification or amendment of this Agreement shall be binding unless
executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not
similar), nor shall such waiver constitute a continuing waiver. 

        12.4    Subrogation.    In the event of full payment under this Agreement, the Company shall be subrogated to the
extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all documents required and shall do all acts that may be necessary or desirable to secure such rights and
to enable the Company effectively to bring suit to enforce such rights. 

        12.5    Counterparts.    This Agreement may be executed in counterparts, which shall together constitute a single
agreement. 

        12.6    Successors and Assigns.    The terms of this Agreement shall bind, and shall inure to the benefit of, the
successors and assigns of the parties hereto, and in particular shall be binding upon any Company into which the Company is merged or consolidated and any corporation or other entity that comes within
the definition of the "Company" under the provisions of Section 1 of this Agreement. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company
would be required to perform if no such succession had taken place. 

        12.7    Notice.    All notices, requests, demands and other communications under this Agreement shall be in writing
and shall be deemed duly given: (a) if delivered by hand and signed for by the party addressee; (b) if mailed by certified or registered mail, with postage prepaid, on the third business
day after the mailing date; or (c) the first business day after deposit with an overnight courier, with proof of delivery from the courier requested. Addresses for notice to either party are as
shown on the signature page of this Agreement or as subsequently modified by written notice. 

10

 

        12.8    Governing Law.    This Agreement shall be governed exclusively by and construed according to the laws of the
State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware. 

        12.9    Consent to Jurisdiction.    The Company and the Indemnitee each hereby irrevocably consent to the jurisdiction
of the courts of the State of Delaware for all purposes in connection with any action or proceeding which arises out of or relates to this Agreement. 

        12.10    Attorneys' Fees.    In the event Indemnitee is required to bring any action to enforce rights under this
Agreement (including, without limitation, the expenses of any proceeding described in Section 4), the Indemnitee shall be entitled to all reasonable fees and expenses in bringing and pursuing
such action, unless a court of competent jurisdiction finds each of the material claims of the Indemnitee in any such action was frivolous and not made in good faith. 

[The remainder of this page is intentionally left blank.]

11

 

IN
WITNESS WHEREOF, the parties hereto have entered into this Indemnity Agreement effective as of the date first written above. 

 

			
	KEYNOTE SYSTEMS, INC.	 	INDEMNITEE:
	
By:
                                         
                                     	
 	
                                        
                                          
    
	
Name:
                                         
                               	
 	
Name:
                                         
                                
	
Title:
                                         
                                 	
 	

 
	
Address:  777 Mariners Island Boulevard	
 	
Address:
                                         
                            
	
                 San Mateo, CA 94404	
 	
                                        
                                          
    

 

 12

QuickLinks

Exhibit 10.01

INDEMNITY AGREEMENT

RECITALS

AGREEMENTExhibit 10.54

 

Contractor Information
 Complete all fields.

	
Company   Name
    	
ANIP   Acquisition Company, d/b/a/ ANI Pharmaceuticals, Inc.
    
	
Contract   No.
    	
V797P-2221D
    
	
RFM   Point of Contact
    	
Darlene   Saccoman
    
	
Phone
    	
218-634-3639
    
	
Email
    	
dsaccoman@anipharmaceuticals.com
    
	
Date   Submitted to FSS
    	
08/22/2012
    

 

Schedule Program

Select the Schedule under which you are requesting to add products.

 

o      65IIA Medical Equipment & Supplies

o      65IIC Dental Equipment & Supplies

o      65IIF Patient Mobility Devices

o      65VA X-Ray Equipment & Supplies

o      65VII Invitro Diagnostics, Reagents, Test Kits, and Test Sets

 

Special Item Numbers

Identify Special item Number (SIN) category(ies) under which the proposed products are classified.
  Attach additional sheets as necessary.

 

Type of Administrative Change

1.      o       Company Name Change or Novation

Review FAR 42.12.  Novation and Change-of-Name Agreements, in its entirety and contact your contracting officer to ensure all required documents are submitted with this request.

 

	
Tax Identification Number (TIN)
    
	
Update
    	
o CCR
    	
o   D&B
    

 

2.      o       Contact Information

 

New Telephone Number

 

New Fax Number

 

New Website

 

	
 
    	
 
    	
Old Address
    	
 
    	
New Address
    
	
Address   1
    	
 
    	
 
    	
 
    	
 
    
	
Address   2
    	
 
    	
 
    	
 
    	
 
    
	
City,   State, Zip
    	
 
    	
 
    	
 
    	
 
    
	
Country   If outside the USA
    	
 
    	
 
    	
 
    	
 
    

 

3.      o       Administrative Point of Contact (POC)

 

	
Contract Requirements & Reminders
    	
VA FSS
    	
 
    

 

1

 

POC Name & Title

 

Address

 

Phone Number

 

Fax Number

 

E-mail Address

 

4.      o       Signatory Authority Form

Include a revised Signatory Authority Form with the request.  The form is available online:
 http://www.va.gov/oal/business/fss/modforms.asp

 

5.      x       Product Number Change

Provide the following information for all affected line items.  You may replace this suggested form with your own format as long as it contains all required information and attachments as necessary.  If you are offering multiple line items, please submit all line items on an Excel spreadsheet.

 

	
Old Product#
    	
 
    	
New Product#
    	
 
    	
Product Description
    
	
62559110606
    	
 
    	
62559011016
    	
 
    	
Metoclopramide   Oral Solution, USP 5mg/5mL
    

 

6.      o       Product Description Change

Provide the following information for all affected line items.  If you are offering multiple line items, please submit all line items on an Excel spreadsheet.

 

	
Product Number
    	
 
    	
Current Description
    	
 
    	
Proposed Description
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    

 

7.      x       Miscellaneous Administrative Changes

Provide explanation of changes being proposed on an attachment which do not fit the above administrative changes choices.  (I.e. address change, BPA and/or Incentive Agreement updates, contract administrator, sales point of contact, etc.).  Attach additional sheets as necessary.

 

Update / correct the physical address that is pulled from the D&B portal and then through the SAM portal.

 

8.      o       Tracking Customer

Provide a detailed explanation of the proposed tracking customer change, including why the proposed tracking customer is an appropriate customer in terms of ensuring that awarded Government pricing and

 

	
Addenda   to SF-1449 & Award Summary
    	
VA FSS
    	
 
    

 

2

 

discount terms remain representative of market prices and that the Government will continue to benefit from positive price changes.  Explanation may be written here or provided in a separate document.

 

a. Awarded Tracking Customer
 Provide the name of the current tracking customer:

 

b. Proposed Tracking Customer
 Provide the name of the proposed tracking customer:

 

c. Price Proposal
 Provide the following information for all offered line items.  You may replace this suggested form with your own format as long as it contains all required information and attachments as necessary.  If you are offering multiple line items, please submit all line items on an Excel spreadsheet.

 

	
-
    	
Product   number
    	
-
    	
FSS   modification number that added the product
    
	
-
    	
Product   description
    	
-
    	
Effective   date of the modification
    
	
-
    	
Commercial   list price
    	
-
    	
Awarded   FSS tracking customer ratio
    
	
-
    	
MFC   name
    	
-
    	
Proposed   tracking customer
    
	
-
    	
MFC   price
    	
-
    	
Tracking   customer percentage discount off list price
    
	
-
    	
MFC   percentage discount off list price
    	
-
    	
Tracking   customer net price
    
	
-
    	
Additional   discounts or concessions
    	
-
    	
Tracking   customer sales (12 months
    
	
-
    	
FSS   percentage discount off list price
    	
-
    	
Additional   comments
    
	
-
    	
FSS   price without IFF
    	
 
    	
 
    
	
-
    	
FSS   price with IFF
    	
 
    	
 
    

 

Verification

x I verify that all of the information supplied in this request is current, accurate, and complete.

x I verify that the signatory of this document is an authorized signatory for the company.

 

Disclaimer: Except as provided herein, all terms and conditions of the subject VA Federal Supply Schedule contract, remain unchanged and in full force and effect.

 

RFM Certification & Authorized Signature

 

	
/s/   Charlotte C. Arnold VP & CEO
    	
 
    	
August 22,   2012
    
	
Signature   and Title of authorized representative
    	
 
    	
Date
    

 

3

	
  

  	
  04 — Vendor
  Response Document M5-Q50A-03-R4 SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL
  ITEMS OFFEROR TO COMPLETE BLOCKS 12, 17 & 30 1. REQUISITION NUMBER N/A
  PAGE 1 of 2. CONTRACT NO. V797P - 22210 3. AWARD/EFFECTIVE DATE 7-15-12 4.
  ORDER NO. MODIFICATION NO. N/A 5. SOLICITATION NO. M5-Q50A-03-R4 6. SOLICITATION
  ISSUE DATE 10/22/2010 7. FOR SOLICITATION INFORMATION CALL: a. NAME: FEDERAL
  SUPPLY SCHEDULE HELPDESK b. TELEPHONE NO. (No Collect Calls) (708) 786-7737 8.
  OFFER DUE DATE/LOCAL TIME: N/A 9. ISSUED BY CODE VA National Acquisition
  Center Federal Supply Schedule Service 001AL-A2-2 PO Box 76, Bldg 37 Hines,
  IL 60141 Overnight Delivery should be mailed or hand delivered to the address
  located in Block 16 10. THIS ACQUISITION IS UNRESTRICTED OR See page 4 of the
  Read Me First document for NAICS codes and size standards under the
  solicitation. See Clause A-FSS-31 SET ASIDE FOR: SMALL BUSINESS HUBZONE SMALL
  BUSINES EMERGING SMALL BUSINESS SERVICE DISABLED VETERAN OWNED SMALL BUSINESS
  8(A) 11. DELIVERY FOR FOB DESTINATION UNLESS BLOCK IS MARKED SEE SCHEDULE 12.
  DISCOUNT TERMS Net 60 Days A 13a. THIS CONTRACT IS A RATED ORDER UNDER DPAS
  (15 CFA 700) 13b. RATING 14. METHOD OF SOLICITATION RFQ IFB RFP 15. DELIVER
  TO CODE TO BE SHOWN ON EACH ORDER ISSUED UNDER ANY CONTRACT RESULTING FROM
  THIS SOLICIATION 16. ADMINISTERED BY CODE VA NATIONAL ACQUISITION CENTER
  FEDERAL SUPPLY SCHEDULE SERVICE 001AL-A2-2 1st AVENUE, 1 BLOCK NORTH OF 22nd
  STREET BLDG 37 HINES, IL 60141 17a. CONTRACTOR/OFFEROR CODE FACILITY CODE ANIP
  Acquisitions Company, dba ANI Pharmaceuticals, Inc. 210 Main Street West, PO
  BOX 370 Baudette MN, 56623 DUNS 14-559-8013 TELEPHONE NO. 218-834-3100 18a.
  PAYMENT WILL BE MADE BY CODE SEE BLOCK 15

   

  17B. CHECK IF
  REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER 18b. SUBMIT INVOICES TO
  ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED SEE ADDENDUM 19.
  ITEM NO. 20. SCHEDULE OF SUPPLIES/SERVICES 21. QUANTITY 22. UNIT 23. UNIT
  PRICE 24. AMOUNT FSC CLASS 6510 6515 6530 6532 FSC Group 65, Part I, Section B
  Drugs, Pharmaceuticals & Hematology Related Products See Continuation of
  SF-1449 for Schedule of Items (Attach Reverse and/or Attach Additional Sheets
  as Necessary) 25.ACCOUNTING AND APPROPRIATION DATA SEE BLOCK 15 26. TOTAL
  AWARD AMOUNT (For Govt. Use Only) ESTIMATED VALUE $ 225,000

   

   27a. SOLICITATION INCORPORATES BY REFERENCE
  FAR 52.212-1. 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA ARE
  ARE NOT ATTACHED. 27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR
  52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA ARE ARE NOT ATTACHED. 28.
  CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN 1 COPIES TO ISSUING
  OFFICE. CONTRACTOR AGREES TO FURNISH AND DELIVER ALL ITEMS SET FORTH OR
  OTHERWISE IDENTIFIED ABOVE AND ON ANY ADDITIONAL SHEETS SUBJECT TO THE TERMS
  AND CONDITIONS SPECIFIED. 29. AWARD OF CONTRACT: REFERENCE FPR OFFER DATED
  7-2-12 YOUR OFFER ON SOLICITATION (BLOCK 5), INCLUDING ANY ADDITIONS OR
  CHANGES WHICH ARE SET FORTH HEREIN, IS ACCEPTED AS TO ITEMS: See Summary of
  Award. 30a. SIGNATURE OF OFFEROR/CONTRACTOR [ILLEGIBLE] 30b. NAME AND TITLE
  OF SIGNER (TYPE OR PRINT) Charlotte C. Arnold 30c.DATE SIGNED [ILLEGIBLE]
  31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER) [ILLEGIBLE]
  Contracting Officer 31b. NAME OF CONTRACTING OFFICER (Type or print) [ILLEGIBLE]
  31c. DATE SIGNED 7/12/12 AUTHORIZED FOR LOCAL REPRODUCTION PREVIOUS EDITION
  IS NOT USABLE STANDARD FORM 1449 (REV. 3/2005) Prescribed by GSA - FAR (48
  CFR) 53.212 

   

  Contract
  Requirements & Reminders VA FSS Page | 4 10506000 

  

 

 

	

    	
DEPARTMENT OF VETERANS AFFAIRS
   Office of Acquisition, Logistics, and Construction
   National Acquisition Center
   P.O. Box 76
   Hines, IL 60141
    

 

In Reply Refer To:  003A4B

 

ANIP Acquisitions Company, dba ANI Pharmaceuticals, Inc 
 Charlotte Arnold
 210 Main Street West, PO Box 370
 Baudette MN, 56623

 

RE:  Department of Veterans Affairs Federal Supply Schedule Contract Award

 

Dear Ms. Arnold:

 

Enclosed is your firm’s copy of Federal Supply Schedule Contract V797P-2221D(1), effective July 15, 2012 through July 14, 2017 for items awarded under 651B select from drop down menu contract under Federal Supply Schedule Solicitation M5-Q50A-03- R4.  This letter outlines the initial requirements of your newly awarded contract and also provides information on several clauses that you should be aware of for future contract actions.

 

The information in this letter and the documents referenced in the attached Contract Requirements and Reminders section are available via the Federal Supply Schedule Web Portal:  http://www.fss.va.dov

 

Thank you in advance for your attention to these matters.  If you have any general questions, please contact your assigned contract specialist, JoLena M. Perkin, at (708) 786-4945 or via email at jolena.perkin@va.gov.

 

	
/s/   JoLena M. Perkin
    	
 
    

 

JoLena M. Perkin
 Contract Specialist
 VA National Acquisition Center 
 Federal Supply Schedule

 

Enclosures
 1.  Contract Requirements & Reminders
 2.  SF-1449
 3.  Addendum to SF-1449 Summary of Award
 4.  Awarded Pricelist

 

(1)  The use of Government contract to solicit Government business for non-contract products is fraudulent and subject prosecution

 

	
Addenda   to SF-1449 & Award Summary
    	
VA FSS
    	
 
    

 

5

 

Sales Reporting & Industrial Funding Fee collection

DUE: WITHIN 60 CALENDAR DAYS OF THE END OF THE REPORTING QUARTER

 

Sales Reporting

 

Clause 552.238-74, Industrial Funding Fee and Sales Reporting requires that you submit, quarterly, the dollar value (in U.S. dollars and rounded to the nearest whole dollar) for all sales under the contract during the preceding 3-month period, to include any partial month.  This process is currently completed on-line through the VA Sales Portal.

 

To access the VA Online Sales Reporting System, visit https://vasalesportal.qsa.gov.

 

When you first access this system, you will need to setup an account profile by clicking “Register” in the upper left-hand corner of the page and completing all required fields.  Once you have submitted your registration information, your account will be routed to our office for verification and activation.  You will receive a notice informing you that the account has been activated.  At that time you will be able to submit your quarterly sales information, along with electronic payment for any Industrial Funding Fee (IFF) funds due.  Please note the following:

 

1.              These sales must be loaded on the GSA/VA web portal on or before the 60th calendar day following the completion of each quarter of the contract (any partial month, is to be considered as 1 month for reporting purposes).

 

2.              Sales for orders that extend beyond the contract period will be reported within 60 days of final payment.

 

3.              You must log in to the sales portal and enter zeroes into the system is no sales occur during the reporting period.

 

4.              A close out report entered in to the system within 120 days after the expiration date of the contract is also required.

 

Additionally, the Government reserves the right to inspect, without further notice, such records of the company that pertain to sales under this contract.  Further, failure or refusal to furnish the required reports or falsification thereof shall constitute cause for terminating the contract for default in accordance with the provisions of your contract.

 

Industrial Funding Fee Collection

 

Clause 552.238-74 also requires you to pay the Department of Veterans Affairs (DVA), an Industrial Funding Fee (IFF) at the end of each contract quarter.  The IFF can be paid at the same time as the sales are loaded into the database.  The IFF equals a percentage of the total sales reported to the VA Sales Portal(2).  The IFF reimburses the DVA for the costs of operating portions of the Federal Supply Schedule Program and recoups its operating costs from ordering activities.  This fee will be included in the awarded

 

(2)  The percentage to be paid can be found in the 552.238-74 Industrial Funding Fee and Sales reporting clause of the solicitation

 

	
Contract Requirements & Reminders
    	
VA FSS
    	
 
    

 

1

 

price(s) and reflected in the total amount charged to ordering activities.  Remittance for the IFF sales information can be submitted via the VA Sales Portal.

 

The IFF amount due shall be paid by ACH, electronic funds transfer or through the VA Sales Portal.  Where multiple Special Item Numbers (SINs) and/or contracts are involved, the IFF may no longer be consolidated into one submission.  The following information is required for IFF payments made via ACH/Electronic Transfer of Funds

 

Receiver Information

 

	
Company Name
    	
 
    	
Department of Veterans Affairs
    
	
Street   Address f P.O. Box
    	
 
    	
P.O. Box   7005
    
	
City,   State, Zip Code
    	
 
    	
Hines, IL_   60141
    
	
Company   Contact
    	
 
    	
Annette   Crayton
    
	
Contact   Phone
    	
 
    	
708   786 7523
    
	
Federal   Taxpayer ID Number
    	
 
    	
74   1612229
    
	
 
    	
 
    	
 
    
	
Receiver   Bank Account Information
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Receiving   Bank Name
    	
 
    	
Department   of Treasury
    
	
Receiving   Bank Contact
    	
 
    	
Cash   Link ACH Receiver
    
	
Contract   Phone
    	
 
    	
301   887 6600
    
	
Receiving   Bank City, State
    	
 
    	
Richmond,   VA
    
	
Receiving   Bank Routing/Transit Number
    	
 
    	
051036706
    
	
Receiving   Bank Capability
    	
 
    	
CCD+
    
	
Receiver’s   Account Number
    	
 
    	
220020
    
	
Indicate   version of 820 ACH Format used by receiving bank
    	
 
    	
Standard
    

 

Additional information on the IFF and Sales Reporting requirements can be found online:
 http://www.va.gov/oalibusiness/fss/sales.asp

 

FSS Price List Requirements

 

Important Notices

 

1.                                      All pricelists must be submitted within the time frames identified in this letter.

 

2.                                      When requesting a modification to your awarded FSS contract, all pricelists must be updated within 30 days upon receipt of a signed SF-30 document.

 

3.                                      The accuracy of information and computation of prices is the responsibility of the Contractor.

 

	
Addenda   to SF-1449 & Award Summary
    	
VA FSS
    	
 
    

 

2

 

FSS Contract Price List(3)
  DUE: WITHIN 30 DAYS AFTER DATE OF CONTRACT AWARD

 

Contractors are required to prepare and submit a paper pricelist for review.

 

Prior to formally printing and distributing your FSS Paper Pricelist you are required to submit two “proof” copies of your proposed FSS Contract Pricelist to your assigned contracting officer (CO) for their review.  This “proof” shall include a cover page and address each point outlined in the clause.  Upon approval, one “proof’” copy will be returned to you with further instructions for formal printing and distribution.  Failure to follow these instructions may cause you to reprint your FSS price list.

 

If you choose to use your commercial catalog as your VA FSS contract price list all non-accepted/awarded items must be lined out or deleted and presented in an acceptable manner determined by the contracting officer (CO).

 

NAC-CM Price List & Contract Catalog Search Tool (CCST)

DUE: WITHIN 30 DAYS AFTER DATE OF CONTRACT AWARD

 

The contractor is responsible for maintaining the National Acquisition Center Contract Management (NAC-CM) database(4).

 

The information in this database populates the National Acquisition Center Contract Catalog Search Tool, which allows facilities to browse medical/surgical and pharmaceutical products and services available under Federal Supply Schedule contracts.

 

The search tool allows the user to locate items using a variety of search criteria, including item description, special item number (SIN) and contract number.  Detailed information is available regarding both the item and the vendor, including contract number; contractor name; contract terms; ordering information; vendor point-of contacts; NAC contracting officer information; and the program/schedule under which it is awarded.

 

The CCST is available online at: http://www.va.gov/nac/.

 

GSA Advantage! Price Lists(5)
  DUE: WITHIN 6 MONTHS AFTER DATE OF CONTRACT AWARD

 

NOTE: This clause does not apply to vendors awarded a contract for 65IB Drugs, Pharmaceuticals; & Hematology Related Products SINs that require a prescription

 

Participation in GSA Advantage! is mandatory for all VA FSS contractors (unless otherwise noted).

 

(3)  I-FSS-600 Contract Price Lists (Jul 2004)(VARIATION) for 65IIA Medical Equipment &Supplies contracts only AS1521 Contract Price Lists (Jun 2005) for 65IB Drugs, Pharmaceuticals, & Hematology related products contracts only I-FSS-600 Contract Price Lists (JUL 2004) used for all other Commodities contracts.

(4)  Blank spreadsheet and instructions for completion are enclosed.

(5)  I-FSS-597 GSA Advantage!TM (SEP 2000)

 

3

 

GSA Advantage! is a menu-driven database system that provides contracting officers and purchasing agents with on-line access to all VA Federal Supply Schedule contracts, including the option to purchase online with a P-Card.

 

There is no cost associated with submitting your electronic catalog (SCAT) through GSA’s Schedule Input Program (SIP).  Likewise, there is no additional charge for processing orders placed through GSA Advantage!

 

The most recent release of the SIP can be downloaded from http://vsc.gsa.gov/sipuser/sip download.cfm; however, if you prefer, you may work with a third-party service to publish your contract information on GSA Advantage!  (NOTE:  these companies charge a fee for their services).

 

GSA Advantage! PO Portal

 

The “PO Portal” gives VA FSS Schedule contractors quick and easy access to purchase orders placed by federal agencies using GSA Advantage! or eBuy.  Using this website you may view, print, or download your purchase orders.  In addition, you may easily send status for each order and status information you send is provided directly to the ordering customer(s) keeping them better informed and eliminating the need to contact you for order status.

 

Registration for the PO Portal can only be accessed via a GSA generated email notice.  This email will contain a link to the registration page.  A notice to register will only be sent to the contractor once an order is received by GSA.

 

Additional Information regarding these electronic tools can be found online:

 

VA eTools:  http://www.va.gov/oal/business/fss/etoolsVA.asp
 GSA eTools:  http://www.va.qov/oal/business/fss/etoolsGSA.asp

 

Request for Modification (RFM)

 

You may request a modification to your awarded contract at any time throughout the term of the contract for: product addition, product deletions, price increases, price decreases, administrative changes (including changes to awarded terms and conditions).  Each request must conform to the requirements identified in the solicitation and all information must be current, accurate, and complete so the assigned contracting officer may make a fair and reasonable determination.

 

Important Notices

 

1. Unless otherwise noted or agreed upon, all solicitation clauses and awarded terms and conditions apply to any resultant contract modification.

 

4

 

2.  All contract modifications must be emailed to helpdesk.ammhinfss@va.dov with the subject line “RFM — Contract Number — FSS Schedule’ (e.g. RFM-V797P/D-XXXXX-651B).  As this email address is the central portal for the FSS Service, modification requests that do not include this reference may be misdirected and thereby the review and process of your request may be delayed.

 

3.  Unless otherwise directed, we do NOT accept hard copies of RFMs.  If the electronic file is 5mb or larger, please submit the RFM package on CD to our mailing address.

 

4.  The effective date of all awarded modifications will occur on either the 1st or 15th of the month.  The effective date of the modification will be assigned by the approving Contract Officer.

 

5.  Approval of the RFM will be evidenced by contractor receipt of a SF-30 document signed by a NAC FSS Contracting Officer.

 

The most recent version of the modification form can be found online:
 http://www.va.gov/oal/business/fss/modForms.asp

 

Additional information about the modification process can be found online:
 http://www.va.qovioal/businessfiss/rfmProcess.asp

 

VA National Acquisition Center 
 Federal Supply Schedule Service 
 PO Box 76, Bldg 37
 1st Ave, North of Cermak Road 
 Hines, IL 60141

 

Annual Registration Requirements

 

Affirmative Action Plan(6)

DUE: WITHIN 120 DAYS AFTER DATE OF CONTRACT AWARD (IF REQUIRED)

 

If the estimated value of your contract exceeds $50,000 and your firm has 50 or more employees, your firm is required to develop and maintain a written Affirmative Action Plan (AAP) for each of its establishments.  You may seek technical assistance from the Office of Federal Contract Compliance Programs (OFCCP) online - http://www.dolciovidol/topic/hiring/affirmativeact.htm; this website provides useful contact information as well as a sample AAP for your reference.

 

You are to keep a copy of your AAP on file and, if requested, provide a copy to OFCCP in the event of a compliance review.  In the event of an OFCCP review, this office requests that you submit confirmation of your compliance via fax or email to your assigned Contracting Officer.

 

Central Contractor Registration

 

Contractors must renew their Central Contractor Registration (CCR) annually or the CCR database will cancel the registration.  You may renew and update your CCR registration online:  http://www.ccroov.

 

(6)  Affirmative Action (AA) Compliance (41 CFR 60-1 & 60-2)(52.212-3(d))

 

5

 

Online Representations and Certifications Application

 

If your firm completed the Online Representations and Certifications Application (ORCA) in lieu of paragraphs (c) through (m) of 52.212-3 Offer Representations and Certifications — Commercial Items of the solicitation, your firm must renew its ORCA application annually or the registration will be cancelled.  You may renew and update your ORCA registration online: https://orca.bpn.gov/.

 

Vets-100

 

Your firm is required to file a VETS-100 report with the Department of Labor (DOL) by September 30th of each year of the contract.  The contractor is required to contact the Department of Labor by phone at (703) 461-2460 or website http://wvvw.dol.gov/vets/procirams/fcp/main.htm to obtain the necessary information to complete the VETS-100 report.

 

Other compliance requirements can be found online:
 http://www.va.gov/oal/business/fss/cornpliance.asp

 

EEO/Fair Labor Standards Act Posters

 

Finally, the Department of Labor requires federal contractors to post posters describing the Equal Employment Opportunity Act and the Fair Labor Standards Act in a prominent location for the duration of your contract.

 

These are available online at: http://www.dol.gov/compliance/topics/posters.htm

 

Useful Web Sites

 

	
VA   Federal Supply Schedule Service
    FSS Help Desk
    	
 
    	
http://www.fss.va.gov
   http://www.va.gov/oal/businessifss/contacts.asp
    
	
VA   FSS Social Media
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 VA FSS Service Linkedln
    	
 
    	
http://www.linkedin.com/pub/va-fss-service/34/166/711
    
	
 
    	
 
    	
 
    
	
 VA FSS Service GSA Interact
    	
 
    	
http://interact.gsa.gov/users/va-fss-service
    
	
 
    	
 
    	
 
    
	
 RSS Feed
    	
 
    	
http://www.fss.va.gov/pressreleases/summary.asp
    
	
Managing   Your VA FSS Contract
    	
 
    	
http://www.va.gov/oal/business/fss/contractors.asp
    
	
VA   FSS Modification Forms
    	
 
    	
http://www.va.gov/oal/business/fss/modForms.asp
    
	
FSS   Sales Reporting & Industrial Funding Fee
    	
 
    	
http://www.va.gov/oal/business/fss/sales.asp
    
	
FSS   Price List Requirements
    	
 
    	
http://www.va.gov/oal/business/fss/contractors.asp
    
	
NAC   Contract Catalog Search Tool
    	
 
    	
http://www.va.gov/nac
    
	
GSA   Advantage! Vendor Start-Up Kit
    	
 
    	
https://vsc.qsa.gov/sipuser/startup   kit.cfm
    
	
GSA   Vendor Support Center
    	
 
    	
http://www.vsc.gsa.gov
    
	
GSA   Schedule Input Program (SIP)
    	
 
    	
http://vsc.qsa.gov/sipuserfsip_download.cfm
    
	
GSA   SIP Training (Products & Services)
    	
 
    	
https://vsc.gsa.gov/training/online_training_req.cfm
    

 

6

 

	
GSA Advantage! PO Portal
    	
 
    	
https://www.poportal.qsa.gov
    
	
Annual   Registration Requirements
    	
 
    	
 
    
	
Affirmative   Action Plan
    	
 
    	
http://www.dol.gov/ofccpAndex.htm
    
	
CCR
    	
 
    	
http://www.ccr.gov
    
	
ORCA
    	
 
    	
https://orca.bpn.gov/
    
	
Vets-100
    	
 
    	
http://www.doI.gov/vets/programs/fcp/main.htm
    
	
EEO/Fair   Labor Standards Act Posters
    	
 
    	
http://www.dol.goy/compliance/to   pics/posters.htm
    

 

7

 

 

Addenda to SF-1449
 Summary of Award

 

VA FSS Contract V797P-2221D

 

The use of this Government contract to solicit Government business for non-contract products is fraudulent and subject to prosecution.

 

 

Contract Documents

 

ANIP Acquisition Company, dba ANI Pharmaceuticals 65I8
  Drugs, Pharmaceuticals and Hematology Products contract under Federal Supply Schedule Solicitation M5-Q50A-03- R4, effective 7/15/2012 through 7/14/2017, consists of the following documents:

 

	
FAR   52.212-4 Contract Terms and Conditions — Commercial Items and Addenda
    
	
FAR   52.212-5 Contract Terms and Conditions Required to Implement Statutes or   Executive Orders — Commercial Items
    
	
The   contractor will participate in Public Law 109-364 Disaster Recovery   Purchasing Program.
    
	
The   contractor will participate in Public Law 111-5 American Recovery and   Reinvestment Act.
    

 

	
Amendment(s)
    	
 
    	
4   Amendments
    
	
Proposal
    	
 
    	
ANIP   Acquisition Company, dba ANI Pharmaceutical offer dated 8/9/2011 revised   6/28/2012
    
	
Revision(s)   — revise to be same as cover page section
    	
 
    	
9/10/18/11,   5/4/12, and 6/28/12
    
	
Final   Proposal Revision Letter
    	
 
    	
7/2/12
   Charlotte C. Arnold, VP and CFO
    
	
Subcontracting   Plan
    	
 
    	
N/A
    
	
Commercial   Pricelist
    	
 
    	
ANI   Rx Product List June 2012
    
	
Awarded   Pricing
    	
 
    	
See   awarded pricing attachment
    

 

a. Pricing Terms and Conditions as agreed to are listed below:

 

	
Awarded   Special Item 
   Number(s) & Maximum Order
    	
$250,000   per item 
   $1,000,000 per order
    
	
Basic   Discount
    	
42-2A:   37% to 48% 
   42-2B: 42.31% to 88.64%
    
	
Basic   Discount (covered drug 
   “Dual Pricing”
    	
Not   Applicable
    
	
Quantity   Discount (Per SIN)
    	
None
    
	
Payment   Terms
    	
Net   60 Days
    
	
Minimum   Order
    	
1   Case
    
	
Standard   Delivery Time
    	
10   Days After receipt of order (ARO)
    
	
Expedited   Delivery Time
    	
2   Days After receipt of order (ARO) ordering facility responsible for the   difference in stardard and expedited delivery
    
	
FOB   Point(s)
    	
FOB   Destination within the 48 Contiguous states and DC, POE to Alaska, Hawaii,   and
    

 

2

 

	
 
    	
Puerto   Rico
    
	
Warranty   Provision
    	
Governments   Warranty 52.212-4 (o)(p)
    
	
Returned   Goods Policy
    	
See   Attachment 2
    
	
Installation
    	
N/A
    
	
Training
    	
N/A
    
	
Annual   Rebate
    	
N/A
    
	
Credit   Card Acceptance
    	
No   the offeror does not accept credit cards 
   Not Applicable.  The offeror does not   accept cc, Waived due to Public Law 102-585
    
	
Rental/Lease   Agreement
    	
N/A
    
	
Service   Agreement
    	
N/A
    
	
Other
    	
N/A
    
	
Commercial   Price List
    	
June 2012
    
	
No   Awards
    	
NDC’s 62559-1110-01, and 62559-1110-07
    

 

b. Tracking Customer

552.238-75 Price Reduction Clause and 552.243-72 Modifications for the purpose of the Price Reduction provisions and Price Increase provisions of this contract, the Government and contractor agree that this contract shall be predicated on the following customer(s) or category(ies) of customer(s): “All Commercial Customers for 42-2A, and CVS, MHA, and Walgreens for 42-2B”.  During the course of this contract, for any sales under the maximum order, the price relationship of Where the FCP is the awarded selling price, the tracking customer ratio does not apply until the tracking customer price falls below the FCP.  At that time a 1:1 ratio applies for all 42-2A, the ratio for 42-28 is .98 to 1:00 and effective immediately shall be maintained.  This is not applicable for deviation sales previously disclosed.

 

If the identified tracking customer’s contract/agreement has been canceled, terminated, has expired, or the tracking customer has merged with another group, the assigned contract specialist shall be notified within 10 days after the event occurs, and if possible, before the event occurs.  At such time the Contractor will negotiate in good faith with the Contracting Officer to establish a successor tracking customer.

 

c. Economic Price Adjustment

552.216-70 Economic Price Adjustment Clause — FSS Multiple Award Schedule Contracts (of the solicitation applies to all items awarded under this contract.

 

d. Tax ID Number

Your Tax I.D. number may be included on the published pricelist to facilitate payment by ordering activities.

 

3

 

The sole purpose of funds provided by the accounting data in Block 25 of the SF1449 is to fund the guaranteed minimum of $2,500 as stated in contract clause I-FSS-106; however, the funds obligated at time of award do not constitute an order for supplies or services under this contract.

 

4

 

 

Rx Product List - Effective June 2012

 

	
NDC
    	
 
    	
Product Description
    	
 
    	
National
   Brand
   Equivalent
    	
 
    	
Country
   of Origin
    	
 
    	
Size
    	
 
    	
Case
   Pack
    	
 
    	
Inner
   Pack
    	
 
    	
AWP
    	
 
    	
WAC
    	
 
    
	
42769-1380-7
    	
 
    	
Hydrocortisone   Rectal Suspension, USP (Retention) 100mg/60mL
    	
 
    	
Cortenema®
    	
 
    	
USA
    	
 
    	
7   x 60mL
    	
 
    	
12
    	
 
    	
7
    	
 
    	
$
    	
74.66
    	
 
    	
$
    	
45.35
    	
 
    
	
62559-1110-1
    	
 
    	
Cortenema® (Hydrocortisone Retention Enema)
    	
 
    	
Cortenema®
    	
 
    	
USA
    	
 
    	
1   x 60mL
    	
 
    	
60
    	
 
    	
0
    	
 
    	
$
    	
12.42
    	
 
    	
$
    	
9.28
    	
 
    
	
62559-1110-7
    	
 
    	
Cortenema® (Hydrocortisone Retention Enema)
    	
 
    	
Cortenema®
    	
 
    	
USA
    	
 
    	
7   x 60mL
    	
 
    	
12
    	
 
    	
7
    	
 
    	
$
    	
83.89
    	
 
    	
$
    	
54.58
    	
 
    
	
62559-110-16
    	
 
    	
Metocloprarnide   Oral Solution USP 5mg/5mL,
    Previsous Code 62559-1106-6
    	
 
    	
Reglan®
    	
 
    	
USA
    	
 
    	
16   oz
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
18.70
    	
 
    	
$
    	
6.50
    	
 
    
	
62559-149-01
    	
 
    	
Estreified   Estrogens and Methyltestosterone Tablets 1.25 mg/2.5 mg
    Previous Code 62559-1490-0
    	
 
    	
Estratest®
    	
 
    	
China
    	
 
    	
100s
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
213.75
    	
 
    	
$
    	
135.00
    	
 
    
	
6259-150-01
    	
 
    	
Estreified   Estrogens and Methyltestosterone Tablets 0.625 mg/1.25 mg
    Previous code 6259-1507-0
    	
 
    	
Estratest   HS®
    	
 
    	
India
    	
 
    	
100s
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
177.95
    	
 
    	
$
    	
112.00
    	
 
    
	
62559-153-04
    	
 
    	
Opium   Tincture, USP (Deodorized, (10 mg/mL)
    	
 
    	
N/A
    	
 
    	
USA
    	
 
    	
118   mL
   (4 fl oz)
    	
 
    	
6
    	
 
    	
0
    	
 
    	
$
    	
740.00
    	
 
    	
$
    	
450.00
    	
 
    
	
62559-158-01
    	
 
    	
Fluvoxamine   Maleate Tablets, USP 25mg
    Previouse Code 42769-1222-0
    	
 
    	
Luvoxe®
    	
 
    	
USA
    	
 
    	
100s
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
230.00
    	
 
    	
$
    	
55.00
    	
 
    
	
62559-159-01
    	
 
    	
Fluvoxamine   Maleate Tablets, USP 50 mg
    Previouse Code 42769-1225-0
    	
 
    	
Luvoxe®
    	
 
    	
USA
    	
 
    	
100s
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
257.00
    	
 
    	
$
    	
60.00
    	
 
    
	
62559-160-01
    	
 
    	
Fluvoxamine   Maleate Tablets, USP 100 mg
    Previouse Code 42 769-122 1-0
    	
 
    	
Luvoxe®
    	
 
    	
USA
    	
 
    	
100s
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
263.00
    	
 
    	
$
    	
65.00
    	
 
    
	
62559-165-01
    	
 
    	
Reglan®   (Metoclopramide tablets, USP) 5 mg
    	
 
    	
Reglan®
    	
 
    	
USA
    	
 
    	
100s
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
248.44
    	
 
    	
$
    	
19835
    	
 
    
	
62559-166-01
    	
 
    	
Reglan®   (Metoclopramide tablets, USP) 10 mg
    	
 
    	
Reglan®
    	
 
    	
USA
    	
 
    	
100s
    	
 
    	
12
    	
 
    	
0
    	
 
    	
$
    	
248.44
    	
 
    	
$
    	
198.75
    	
 
    

 

5

 

	
SIN#
    	
 
    	
NDC 1
    	
 
    	
NDC 2
    	
 
    	
NDC 3
    	
 
    	
Generic Name
    	
 
    	
Trade name
    	
 
    	
Package
   Size
    	
 
    	
Unit of
   Sale
    	
 
    	
Quantity in
   Unit of
   Packaging
    	
 
    	
Tracking
   Ratio
    	
 
    	
FSS Single
   Price with
   IFF ($)
    	
 
    	
Awarded
   “A”
    	
 
    
	
42-2A
    	
 
    	
62559
    	
 
    	
165
    	
 
    	
01
    	
 
    	
Metoclopramide Tablets,   USP 5 mg
    	
 
    	
Reglan (Metoclopramide   Tablets, USP) 5 mg
    	
 
    	
100
    	
 
    	
Each
    	
 
    	
12 Bottles =
   1 Case
    	
 
    	
1.00
    	
 
    	
$
    	
104.56
    	
 
    	
A
    	
 
    
	
42-2A
    	
 
    	
62559
    	
 
    	
166
    	
 
    	
01
    	
 
    	
Metoclopramide Tablets,   USP 10 mg
    	
 
    	
Reglan (Metoclopramide   Tablets, USP) 10 mg
    	
 
    	
100
    	
 
    	
Each
    	
 
    	
12 Bottles =
   1 Case
    	
 
    	
1.00
    	
 
    	
$
    	
126.76
    	
 
    	
A
    	
 
    

 

6

 

	
SIN#
    	
 
    	
NDC 1
    	
 
    	
NDC 2
    	
 
    	
NDC 3
    	
 
    	
Generic Name
    	
 
    	
Trade name
    	
 
    	
Package
   Size
    	
 
    	
Unit of
   Sale
    	
 
    	
Quantity in
   Unit of
   Packaging
    	
 
    	
Tracking
   Ratio
    	
 
    	
FSS Single
   Price with
   IFF ($)
    	
 
    	
Awarded
   “A”
    	
 
    
	
42-2B
    	
 
    	
42769
    	
 
    	
1380
    	
 
    	
7
    	
 
    	
Hydrocortisone Rectal   Suspension, USP
    	
 
    	
Cortenema (Hydrocortisone   Retention Enema)
    	
 
    	
7 x 60 mL
    	
 
    	
Each
    	
 
    	
12 Boxes = 1 Case
    	
 
    	
0.98
    	
 
    	
$
    	
7.61
    	
 
    	
A
    	
 
    
	
42-2B
    	
 
    	
62559
    	
 
    	
1106
    	
 
    	
6
    	
 
    	
Metoclopramide Oral   Solution USP
    	
 
    	
Reglan Syrup
    	
 
    	
16 oz.
    	
 
    	
Each
    	
 
    	
12 Bottle = 1 Case
    	
 
    	
0.99
    	
 
    	
$
    	
3.77
    	
 
    	
A
    	
 
    
	
42-2B
    	
 
    	
62559
    	
 
    	
0158
    	
 
    	
01
    	
 
    	
Fluvoxamine Maleate   Tablets, USP 25 mg
    	
 
    	
Luvox
    	
 
    	
100
    	
 
    	
Each
    	
 
    	
12 Bottle = 1 Case
    	
 
    	
0.99
    	
 
    	
$
    	
6.28
    	
 
    	
A
    	
 
    
	
42-2B
    	
 
    	
62559
    	
 
    	
0159
    	
 
    	
01
    	
 
    	
Fluvoxamine Maleate   Tablets, USP 50 mg
    	
 
    	
Luvox
    	
 
    	
100
    	
 
    	
Each
    	
 
    	
12 Bottle = 1 Case
    	
 
    	
0.99
    	
 
    	
$
    	
7.60
    	
 
    	
A
    	
 
    
	
#REF!
    	
 
    	
62559
    	
 
    	
0160
    	
 
    	
01
    	
 
    	
Fluvoxamine Maleate   Tablets, USP 100 mg
    	
 
    	
Luvox
    	
 
    	
100
    	
 
    	
Each
    	
 
    	
12 Bottle = 1 Case
    	
 
    	
1.00
    	
 
    	
$
    	
10.50
    	
 
    	
A
    	
 
    

 

7

 

	
ANIP   Acquisition Company 
   d/b/a ANI
   Pharmaceuticals, Inc.
    	
 
    	
Company   Policy/Procedure
    	
 
    	
Policy   Number: CP-001 v 1.0 Effective: 01-July-2012
    Supercedes: Rev 2 Dated: Feb 2008
    

 

Return Goods Policy and Procedure
 For the United States Government

Page 8 of 4

 

1.                                      Purpose

The purpose of this policy is to define the parameters under which we will accept goods returned to us from the United States Government, as well as the procedure for handling such returned goods.

 

2.                                      Scope

This procedure will be used when it is necessary to process goods returned from the United States Government.

 

3.                                      Abbreviations

ANI — ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. 
 Customer — United States Government entities
 POD — Proof of destruction
 RGA — Return Goods Authorization

 

4.                                      Definitions

Customer—United States Government entities

 

5.                                      Guidelines

None.

 

6.                                      Responsibilities

The processing of returned goods is the responsibility of Customer Service, Receiving, and Finance.

 

7.                                      Procedure

 

TERMS AND CONDITIONS

 

·                                          ANI reserves the right to refuse return claims in excess of two percent (2%) of the United States Government’s annual purchases.  All returns must be pre-approved by the Customer Service Department, CustomerService@ANIPharmaceuticals.com or 800-434-1121, ext. 3607.  Such pre-approvals shall not affect ANI’s right to determine if the Products do not otherwise qualify as returnable for credit.

 

NON-RETURNABLE ITEMS

 

·                                          Product that is not within ninety (90) days of expiration.

·                                          Product more than twelve (12) months past expiration date.

·                                          Product sold on a non-returnable basis

·                                          Unlabeled

·                                          Partially labeled

·                                          Have been donated

 

8

 

	
ANI   Acquisition Company 

d/b/a   ANI

Pharmaceuticals,   Inc.
    	
 
    	
Company   Policy/Procedure
    	
 
    	
Policy   Number: CP-001 v 1.0 Effective: 01-July-2012

Supercedes:   Rev 2 Dated: Feb 2008
    

 

For Return Goods Policy and Procedure
 the United States Government

Page 9 of 4

 

·                                          Purchased at sacrifice

·                                          Fire or bankruptcy sales

·                                          Sold on a non-returnable basis

·                                          Partial product that was sold in packaging marked “Not for Individual Sale” (such as, but not limited to Hydrocortisone 7’s or Cortenema 7’s)

·                                          Partial product, product with broken seals, or product that has been opened, except where required by law.

·                                          Product damaged at the Customer’s warehouse or store level.

·                                          Product exposed to fire, smoke, heat, water or other adverse environmental conditions, and/or improper handling and/or storage.

·                                          Packages which have been marked or disfigured in any way.

·                                          Packages with missing, torn, damaged or unreadable labels.

·                                          Outdated returns totaling less than $100.00.

·                                          Product that was ordered by the Customer in error, unless ANI receives notification in writing before the products are shipped.

 

Be advised that ANI reserves the right to destroy or deny credit for, products which are not returned in compliance with this policy which are unfit or unsafe for sale, that are returned without prior authorization, or that are destroyed without prior authorization.

 

RETURNABLE ITEMS

 

Outdated and Damaged Goods

 

·                                          Short dated product that is within ninety (90) days of expiration.

·                                          Expired product, but not more than twelve (12) months past expiration date.

·                                          Concealed damage claims made within 60 days of receipt.

·                                          Products damaged in shipping to Customer accompanied by a signed bill of lading noting such damage.  (Claims must be made within 10 days.)

·                                          Product that is shipped to the Customer in error (without having an order for it).  Claims must be made within 10 days of receipt of product.

 

PROCEDURE FOR RETURNING ITEMS

 

·                                          All requests for returns must be in writing via e-mail, mail or fax.

·                                          Requests must include the following

·                                          Customer name

·                                          “Ship to” address if different than “Bill to” address

·                                          Proof of purchase in the form of invoice number of original purchase (If there are multiple items returned from different invoices, then all invoice numbers must accompany the request)

·                                          Item name

·                                          Quantity

 

9

 

	
ANI   Acquisition Company 

d/b/a   ANI

Pharmaceuticals,   Inc.
    	
 
    	
Company   Policy/Procedure
    	
 
    	
Policy   Number: CP-001 v 1.0 Effective: 01-July-2012

Supercedes:   Rev 2 Dated: Feb 2008
    

 

For Return Goods Policy and Procedure
 the United States Government

Page 10 of 4

 

·                                          NDC number

·                                          Lot number

·                                          Expiration date

·                                          Reason for return

·                                          After review, a return authorization number will be issued via fax, e-mail or mail.

·                                          Place the RA# on the outside of all packages or shipments will not be accepted by ANI.

·                                          If customer chooses to destroy product in lieu of returning it, authorization of destruction is required.  Request to destroy should be done when Return Goods Authorization is requested.  Proof of destruction is then required by ANI.

·                                          Destruction without authorization could result in non-payment of credit request

·                                          Credit will not be given for any additional items returned without authorization.

·                                          Customer is responsible for processing fees.

 

All transportation charges for returns must be prepaid by Customer.  When using third party handlers and/or reverse distributors, credit will be issued based upon the reports submitted by the third party handler/reverse distributor.  Fees for the third party service must be paid by the Customer.  ANI will not be responsible for these fees.

 

CREDIT HANDLING

 

·                                          Credit or equivalent replacement product will be issued within thirty (30) days of receipt of outdated, short-dated, or unsalable product accompanied with the pre-approval numbered return authorization form.  Return must be made within thirty (30) days of authorization.

·                                          Credit or equivalent replacement product will be allowed on all ANI products returned in unopened, original labeled package, no more than ninety (90) days prior to expiration and up to one (1) year past expiration date and in accordance with and subject to the other terms and conditions of this Return Goods Policy.  Returns will ‘be credited at the lesser of acquisition cost (contract price) or current price.  Customer will receive a credit memo from ANI.

·                                          ANI reserves the right to destroy, without giving credit for, products which are not returned in compliance with this policy and which are unfit or unsafe for sale.  The return of such products by ANI to the facility submitting the returned products may violate regulations established by the FDA.

 

·                                          Returns should be sent to:

 

ANI Pharmaceuticals, Inc.

210 Main Street W

Baudette, MN 56623

Attn: Warehouse-Returns

 

10

 

	
ANI   Acquisition Company 

d/b/a   ANI

Pharmaceuticals,   Inc.
    	
 
    	
Company   Policy/Procedure
    	
 
    	
Policy   Number: CP-001 v 1.0 Effective: 01-July-2012

Supercedes:   Rev 2 Dated: Feb 2008
    

 

For Return Goods Policy and Procedure
 the United States Government

Page 11 of 4

 

DISCLAIMER

 

ANI products received by ANI not meeting the above guidelines will not be returned and credit will not be issued.  These policies are subject to applicable stale and/or other regulatory agency’s regulations.  Customers must have an open and active account in order to receive credit for approved returned or destroyed merchandise.

 

8.                                      Approvals

 

	
 
    	
 
    	
 
    
	
Leslie Nicholson, Customer Service Associate
    	
 
    	
Date
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Chad Turner, Controller
    	
 
    	
Date
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Charlotte Arnold, Vice President & CFO
    	
 
    	
Date
    

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]